Send a text

Welcome back Rounds Table Listeners!

In this throwback episode, Drs. Mike and John Fralick discuss the use of semaglutide in patients with obesity without diabetes and changes in renal function after starting dapagliflozin in patients with heart failure. Check it out below!

1. Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial (0:00 – 09:40).
2. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (09:40 – 19:24).

And for the Good Stuff:

• How Ozempic and Weight Loss Drugs Are Reshaping Denmark’s Economy (19:24 – 19:58).
• How a Canadian scientist and a venomous lizard helped pave the way for Ozempic (19:58 – 23:36).

Questions? Comments? Feedback? We’d love to hear from you! @roundstable